Heard on the Street: Pfizer’s latest multibillion-dollar deal shows it isn’t backing down from the obesity fight. The stock offers a cheap ticket into the hottest corner of pharma. https://t.co/tD3iq3NtJh ...

Our next guest says this move makes Fiser a more credible threat in the obesity landscape. For more, let's bring in Evan Seagerman, head of healthcare research at Beimo Capital Markets. Evan, great to have you with us.Um, you better you've got a buy rating on on Fizer and a $30 price target. I'm wondering buying this portfolio of very experimental obesity drugs, i.e. phase one drugs effectively. Does this make you a lot more bullish.I am bullish because I think Fizer's foray into obesity has been we've been ...

Pfizer agrees to buy the obesity startup Metsera for an enterprise value of about $4.9 billion to bolster its pipeline after a key weight-loss pill foundered https://t.co/FN4cJqE0SM ...

Pfizer is closing in on a potential $7.3 billion takeover of obesity startup Metsera, the Financial Times reported, citing unidentified people familiar with the matter https://t.co/5fMo7L3DaX ...

Market Sentiment & Competition - Investor sentiment has shifted in favor of Novo Nordisk over Eli Lilly, potentially due to data presented at a conference in Vienna [1] - Novo Nordisk is expanding beyond obesity treatments, addressing concerns like food noise, similar to Eli Lilly's approach [2] - The market is moving towards offering different drug options to cater to various patient segments, considering factors like desired weight loss and side effects [3] Drug Development & Offerings - Novo Nordisk has positive data from both oral and injectable medications [2] - Eli Lilly's Lily Direct program allows patients to access different dosages than standard injections, with some needing only 1 milligram instead of 5 milligrams [5] - Research is exploring ways to counter sarcopenia (muscle loss) associated with significant fat loss during weight loss treatments [6] Prescriber & Patient Considerations - GI side effects, medication adherence, and cost are significant factors for prescribers when choosing medications [2] - Cost is a primary concern for medication uptake [3] - Patients desire options that offer strong weight loss with minimal side effects [3][4]

Globally one-fifth of children aged 5-19 are overweight; of them, half are obese. We explain what’s behind this alarming trend, and why poor countries are particularly ill-equipped to cope https://t.co/oaHV5Q02nm ...

Funny how much higher obesity is in Shanghai vs its surrounding provinces https://t.co/JTGZFRDczg ...

For the first time the number of school-aged children who are obese is higher than those who are severely undernourished, according to a UNICEF report. Which places are worst affected? https://t.co/3uoEZYw2fR ...

Public Health Impact - Approximately 50% of German adults are overweight [1] - This issue costs the German public health system between €27 billion and €90 billion annually [1] Societal Debate - The responsibility for this health problem is a subject of public debate in Germany [1]

Health Initiatives - Health Secretary Robert F Kennedy Jr visited Alaska to explore methods of increasing traditional food consumption among rural Alaska Natives [1] - The initiative aims to address high rates of obesity and heart disease by encouraging alternatives to ultraprocessed foods [1]